Track Myriad Genetics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Myriad Genetics, Inc. MYGN · Stock Open Myriad Genetics, Inc. in new tab

5.66 USD
EPS
-1.35
P/B
2.03
ROE
-40.23
Beta
1.61
Target Price
5.22 USD
Myriad Genetics, Inc. logo

Myriad Genetics, Inc.

🧾 Earnings Recap – Q3 2026

Myriad’s shares rose 4.5% after earnings, with investors likely responding to a modestly higher 2026 revenue outlook, sequential improvement in average revenue per test and the $210 million agreement to sell its Prenatal Health business. The quarter still showed pressure in Prenatal Health volumes and year-over-year declines in Cancer Care average revenue per test.

  • Q3 revenue was $202.7 million. Cancer Care Continuum and Mental Health test volumes grew 4% and 3% year over year, respectively; Prenatal Health volume fell 11%.
  • Average revenue per test increased 1% year over year, versus a 9% decline in Q2. HCT revenue per test was down 6% year over year but up 9% sequentially.
  • Cancer Care Continuum revenue was $124 million, up 1% year over year. Test volume rose 4% to 98,000, while average revenue per test declined 3%.
  • Gross margin improved 130 basis points from Q2 to 67.9%. Adjusted EBITDA improved by $5.3 million quarter over quarter to negative $5.3 million; adjusted EPS was negative $0.11.
  • Myriad raised the midpoint of 2026 revenue guidance modestly, to a range of $780 million to $790 million. The Prenatal Health sale to Labcorp is an all-cash deal for $210 million plus inventory.
📅
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-1.35
Book Value2.81
Price to Book2.03
Debt/Equity77.84
% Insiders3.995%
Growth
Revenue Growth-0.02%
Estimates
Forward P/E-9.23
Forward EPS-0.62
Target Mean Price5.22

DCF valuation

Model fair value for Myriad Genetics, Inc. (MYGN)
Result
Sign in to run the valuation for MYGN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Hold · mean target 5.22 USD (low 2.50, high 8.00) · as of 12 Nov 2026
Low 2.50
Mean 5.22
High 8.00
Price 5.66
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Myriad Genetics, Inc. Logo Myriad Genetics, Inc. Analysis (MYGN)

United States Health Care Official Website Stock

Is Myriad Genetics, Inc. a good investment? Myriad Genetics, Inc. (MYGN) is currently trading at 5.66 USD. Market analysts have a consensus price target of 5.22 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Myriad Genetics, Inc. is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -0.62.

Investor FAQ

Does Myriad Genetics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Myriad Genetics, Inc.?

Myriad Genetics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -1.35.

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Exchange Ticker
NMS (United States) MYGN
FRA (Germany) MYD.F
ASX (Australia) MYD.AX
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2009
3.50 USD
July 1, 2009 1.7500
June 15, 2009 1.7500
Stock Splits
Split Date Split Ratio to 1
Sept. 12, 2000 2:1
March 26, 2009 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion